BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 31236756)

  • 1. Simultaneous PET/MRI in the Evaluation of Breast and Prostate Cancer Using Combined Na[
    Sonni I; Minamimoto R; Baratto L; Gambhir SS; Loening AM; Vasanawala SS; Iagaru A
    Mol Imaging Biol; 2020 Apr; 22(2):397-406. PubMed ID: 31236756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
    Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
    J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases.
    Iagaru A; Mittra E; Dick DW; Gambhir SS
    Mol Imaging Biol; 2012 Apr; 14(2):252-9. PubMed ID: 21479710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What Is the Comparative Ability of 18F-FDG PET/CT, 99mTc-MDP Skeletal Scintigraphy, and Whole-body MRI as a Staging Investigation to Detect Skeletal Metastases in Patients with Osteosarcoma and Ewing Sarcoma?
    Aryal A; Kumar VS; Shamim SA; Gamanagatti S; Khan SA
    Clin Orthop Relat Res; 2021 Aug; 479(8):1768-1779. PubMed ID: 33635285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intra-individual comparison of
    Bénard F; Harsini S; Wilson D; Zukotynski K; Abikhzer G; Turcotte E; Cossette M; Metser U; Romsa J; Martin M; Mar C; Saad F; Soucy JP; Eigl BJ; Black P; Krauze A; Burrell S; Nichol A; Tardif JC
    Lancet Oncol; 2022 Dec; 23(12):1499-1507. PubMed ID: 36343655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pilot prospective evaluation of 99mTc-MDP scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and whole-body MRI for detection of skeletal metastases.
    Iagaru A; Young P; Mittra E; Dick DW; Herfkens R; Gambhir SS
    Clin Nucl Med; 2013 Jul; 38(7):e290-6. PubMed ID: 23455520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET/CT and 99mTc-MDP bone scan.
    Damle NA; Bal C; Bandopadhyaya GP; Kumar L; Kumar P; Malhotra A; Lata S
    Jpn J Radiol; 2013 Apr; 31(4):262-9. PubMed ID: 23377765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by
    Pietrzak A; Czepczynski R; Wierzchoslawska E; Cholewinski W
    Hell J Nucl Med; 2017; 20(3):237-240. PubMed ID: 29177262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
    Qiu ZL; Xue YL; Song HJ; Luo QY
    Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.
    Jambor I; Kuisma A; Ramadan S; Huovinen R; Sandell M; Kajander S; Kemppainen J; Kauppila E; Auren J; Merisaari H; Saunavaara J; Noponen T; Minn H; Aronen HJ; Seppänen M
    Acta Oncol; 2016; 55(1):59-67. PubMed ID: 25833330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is (99m)Tc-MDP whole body bone scintigraphy adjuvant to (18)F-FDG-PET for the detection of skeletal metastases?
    Sahin E; Zincirkeser S; Akcan AB; Elboga U
    J BUON; 2014; 19(1):291-6. PubMed ID: 24659678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Prospective Study Comparing
    Löfgren J; Mortensen J; Rasmussen SH; Madsen C; Loft A; Hansen AE; Oturai P; Jensen KE; Mørk ML; Reichkendler M; Højgaard L; Fischer BM
    J Nucl Med; 2017 Nov; 58(11):1778-1785. PubMed ID: 28798033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the diagnostic accuracy of 99 m-Tc-MDP bone scintigraphy and 18 F-FDG PET/CT for the detection of skeletal metastases.
    Chang CY; Gill CM; Joseph Simeone F; Taneja AK; Huang AJ; Torriani M; Bredella MA
    Acta Radiol; 2016 Jan; 57(1):58-65. PubMed ID: 25533313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design.
    Gerety EL; Lawrence EM; Wason J; Yan H; Hilborne S; Buscombe J; Cheow HK; Shaw AS; Bird N; Fife K; Heard S; Lomas DJ; Matakidou A; Soloviev D; Eisen T; Gallagher FA
    Ann Oncol; 2015 Oct; 26(10):2113-8. PubMed ID: 26202597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (18)F-FDG positron emission tomography/computed tomography and (99m)Tc-MDP skeletal scintigraphy in a case of Erdheim-Chester disease.
    Asabella AN; Cimmino A; Altini C; Notaristefano A; Rubini G
    Hell J Nucl Med; 2011; 14(3):311-2. PubMed ID: 22087457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incremental Value of Cocktail 18F-FDG and 18F-NaF PET/CT Over 18F-FDG PET/CT Alone for Characterization of Skeletal Metastases in Breast Cancer.
    Roop MJ; Singh B; Singh H; Watts A; Kohli PS; Mittal BR; Singh G
    Clin Nucl Med; 2017 May; 42(5):335-340. PubMed ID: 28263210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography.
    Ak I; Sivrikoz MC; Entok E; Vardareli E
    Eur J Cardiothorac Surg; 2010 Apr; 37(4):792-6. PubMed ID: 20015657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective comparison of whole-body bone SPECT and sodium 18F-fluoride PET in the detection of bone metastases from breast cancer.
    Abikhzer G; Srour S; Fried G; Drumea K; Kozlener E; Frenkel A; Israel O; Fogelman I; Kagna O
    Nucl Med Commun; 2016 Nov; 37(11):1160-8. PubMed ID: 27536906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma.
    Mosavi F; Johansson S; Sandberg DT; Turesson I; Sörensen J; Ahlström H
    AJR Am J Roentgenol; 2012 Nov; 199(5):1114-20. PubMed ID: 23096187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.